blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP1526184

EP1526184 - Promoter sequences specific for cells of the B lymphoid lineage and pharmaceutical compositions containing the same [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  30.06.2006
Database last updated on 02.11.2024
Most recent event   Tooltip30.06.2006Application deemed to be withdrawnpublished on 02.08.2006  [2006/31]
Applicant(s)For all designated states
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
101, rue de Tolbiac
75654 Paris Cédex 13 / FR
[N/P]
Former [2005/17]For all designated states
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
101, rue de Tolbiac
75654 Paris Cédex 13 / FR
Inventor(s)01 / Tonelle, Cécile
9, avenue A. Rodin
13470 Carnoux en Provence / FR
02 / Moreau, Thomas
33, rue Falque
13006 Marseille / FR
03 / Chabannon, Christian
9, avenue Taine
13009 Marseille / FR
04 / Imbert, Jean
1, square de l'Eygalier, Parc des 7 collines
13011 Marseille / FR
 [2005/17]
Representative(s)Grosset-Fournier, Chantal Catherine
Grosset-Fournier & Demachy
54, rue Saint-Lazare
75009 Paris / FR
[N/P]
Former [2005/17]Grosset-Fournier, Chantal Catherine
Grosset-Fournier & Demachy, 54, rue Saint-Lazare
75009 Paris / FR
Application number, filing date03292663.624.10.2003
[2005/17]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP1526184
Date:27.04.2005
Language:EN
[2005/17]
Search report(s)(Supplementary) European search report - dispatched on:EP21.04.2004
ClassificationIPC:C12N15/63, A01K67/027
[2005/17]
CPC:
C07K14/70503 (EP); A01K67/0271 (EP); C12N15/63 (EP);
C12N15/85 (EP); A01K2267/03 (EP); A01K2267/0393 (EP);
A61K48/00 (EP); C12N2799/027 (EP); C12N2830/00 (EP);
C12N2830/008 (EP); C12N2830/85 (EP) (-)
Designated contracting statesFR [2006/03]
Former [2005/17]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IT,  LI,  LU,  MC,  NL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:Promotorsequenzen spezifisch für Zellen der B-lymphoiden Reihe und pharmazeutische Zusammensetzungen, welche diese enthalten[2005/17]
English:Promoter sequences specific for cells of the B lymphoid lineage and pharmaceutical compositions containing the same[2005/17]
French:Séquences de promoteurs spécifiques de la lignée cellulaire B lymphoide et compositions pharmaceutiques les contenant[2005/17]
Examination procedure15.11.2005Application deemed to be withdrawn, date of legal effect  [2006/31]
06.03.2006Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time  [2006/31]
Fees paidPenalty fee
Penalty fee Rule 85b EPC 1973
14.12.2005M01   Not yet paid
Additional fee for renewal fee
31.10.200503   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]WO02079418  (SANGAMO BIOSCIENCES INC [US], et al) [X] 1-14 * page 70 - page 72; example 2 * * page 7 - page 8; figure 3 *;
 [X]  - GISLER RAMIRO ET AL, "A human early B-cell factor-like protein participates in the regulation of the human CD19 promoter", MOLECULAR IMMUNOLOGY, (199910), vol. 36, no. 15-16, ISSN 0161-5890, pages 1067 - 1077, XP002274086 [X] 1-14 * abstract *

DOI:   http://dx.doi.org/10.1016/S0161-5890(99)00092-9
 [DX]  - KOZMIK Z ET AL, "THE PROMOTER OF THE CD19 GENE IS A TARGET FOR THE B-CELL-SPECIFIC TRANSCRIPTION FACTOR BSAP", MOLECULAR AND CELLULAR BIOLOGY, (199206), vol. 12, no. 6, ISSN 0270-7306, pages 2662 - 2672, XP001117417 [DX] 1-14 * abstract * * page 2665 - page 2671; figure 9 *
 [DX]  - RIVA A ET AL, "In vivo footprinting and mutational analysis of the proximal CD19 promoter reveal important roles for an SP1/Egr-1 binding site and a novel site termed the PyG box.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 1 AUG 1997, (19970801), vol. 159, no. 3, ISSN 0022-1767, pages 1284 - 1292, XP002274087 [DX] 1-14 * abstract * * page 1285, column R, paragraph 4 - page 1287, column L, paragraph 1 *
 [X]  - MOREAU T (REPRINT) ET AL, "Restriction of EGFP expression in the B-cell lineage, using a lentiviral vector with a sequence derived from the human CD19 promoter", EXPERIMENTAL HEMATOLOGY, (JUL 2003) VOL. 31, NO. 7, SUPP. [1], PP. 95-95. MA 105. PUBLISHER: ELSEVIER SCIENCE INC, 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA. ISSN: 0301-472X., Inst J Paoli I Calmettes, F-13009 Marseille, France, XP001180232 [X] 1-14 * abstract *
 [X]  - MOREAU T (REPRINT) ET AL, "Specificity of EGFP expression in the B-cell lineage using a lentiviral vector with a sequence derived from the human CD19 promoter", MOLECULAR THERAPY, (MAY 2003) VOL. 7, NO. 5, PART 2, PP. S437-S437. MA 1131. PUBLISHER: ACADEMIC PRESS INC ELSEVIER SCIENCE, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA. ISSN: 1525-0016., Inst J Paoli I Calmettes, Ctr Therapie Cellulaire & Gen, F-13009 Marseille, France, XP001180234 [X] 1-14 * abstract *
 [X]  - MOREAU T (REPRINT) ET AL, "Restriction of EGFP expression to B-lymphoid progeny from human CD34(+) cells using a lentiviral vector with sequences derived from the human CD19 promoter.", BLOOD (16 NOV 2003) VOL. 102, NO. 11, PART 2, PP. 491B-491B. MA 5694. PUBLISHER: AMER SOC HEMATOLOGY, 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA. ISSN: 0006-4971., Inst J Paoli I Calmettes, Ctr Therapie Cellulaire & Genet, F-13009 Marseille, France;INSERM, U119, F-13258 Marseille, France, XP009027672 [X] 1-14 * abstract *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.